EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dexamethasone–tamoxifen combination exerts synergistic therapeutic effects in tamoxifen-resistance breast cancer cells

Aliaa I Gaballah, Aliaa A Elsherbiny, Marwa Sharaky, Najat O Hamed, Nahed A Raslan, Abdullah Almilaibary, Reda Mohamed Abdrabbou Fayyad, Mona S Ousman, Ahmed M E Hamdan, Sally A Fahim iD

Bioscience Reports · 31.07.2024 · 44 (7)

DOI: 10.1042/bsr20240367 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioscience Reports, online erschienen am 05.07.2024. Verfasst von Aliaa I Gaballah und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Newgiza University (NGU), Newgiza, km 22 Cairo-Alexandria Desert Road, Giza, P.O. Box 12577, Egypt. Hauptthemen laut MEDLINE: Tamoxifen, Dexamethasone, Drug Resistance, Neoplasm, Breast Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tamoxifen (TAM) is a key player in estrogen receptor-positive (ER+) breast cancer (BC); however, ∼30% of patients experience relapse and a lower survival rate due to TAM resistance. TAM resistance was related to the over expression of SOX-2 gene, which is regulated by the E2F3 transcription factor in the Wnt signaling pathway. It was suggested that SOX-2 overexpression was suppressed by dexamethasone (DEX), a glucocorticoid commonly prescribed to BC patients. The aim of the present study is to explore the effect of combining DEX and TAM on the inhibition of TAM-resistant LCC-2 cells (TAMR-1) through modulating the E2F3/SOX-2-mediated Wnt signaling pathway. The effect of the combination therapy on MCF-7 and TAMR-1 cell viability was assessed. Drug interactions were analyzed using CompuSyn and SynergyFinder softwares. Cell cycle distribution, apoptotic protein expression, gene expression levels of SOX-2 and E2F3, and cell migration were also assessed. Combining DEX with TAM led to synergistic inhibition of TAMR-1 cell proliferation and migration, induced apoptosis, reduced SOX-2 and E2F3 expression and was also associated with S and G2-M phase arrest. Therefore, combining DEX with TAM may present an effective therapeutic option to overcome TAM resistance, by targeting the E2F3/SOX-2/Wnt signaling pathway, in addition to its anti-inflammatory effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TamoxifenDexamethasoneDrug Resistance, NeoplasmBreast NeoplasmsDrug SynergismCell ProliferationHumansFemaleMCF-7 CellsApoptosisCell MovementWnt Signaling PathwayGene Expression Regulation, NeoplasticAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorE2F3 Transcription FactorSOXB1 Transcription Factors

Stichwörter der Autor:innen

E2F3SOX-2breast cancerdexamethasonesynergistic effecttamoxifen-resistance

Substanzen

TamoxifenDexamethasoneAntineoplastic Agents, HormonalE2F3 Transcription FactorSOXB1 Transcription Factors

Autor:innen und Institutionen

  • School of Pharmacy, Newgiza University (NGU), Newgiza, km 22 Cairo-Alexandria Desert Road, Giza, P.O. Box 12577, Egypt.
  • Department of Biochemistry, School of Pharmacy, Newgiza University (NGU), Newgiza, km 22 Cairo-Alexandria Desert Road, Giza, P.O. Box 12577, Egypt.
  • Pharmacology Unit, Department of Cancer Biology, National Cancer Institute, Cairo University, Giza, Egypt.
  • Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, P.O. Box 71666, Riyadh 11597, Saudi Arabia.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo 11651, Egypt.
  • Clinical Pharmacy Program, College of Health Sciences and Nursing, Al-Rayan Colleges, Medina 42541, Saudi Arabia.

ORCID-Profile: Sally A Fahim

Förderung

  • NA

Zitieren

APA

Gaballah, A. I., Elsherbiny, A. A., Sharaky, M., Hamed, N. O., Raslan, N. A., Almilaibary, A., Fayyad, R. M. A., Ousman, M. S., Hamdan, A. M. E., & Fahim, S. A. (2024). Dexamethasone–tamoxifen combination exerts synergistic therapeutic effects in tamoxifen-resistance breast cancer cells. Bioscience Reports, 44(7). https://doi.org/10.1042/bsr20240367

Vancouver

Gaballah AI, Elsherbiny AA, Sharaky M, Hamed NO, Raslan NA, Almilaibary A, et al. Dexamethasone–tamoxifen combination exerts synergistic therapeutic effects in tamoxifen-resistance breast cancer cells. Bioscience Reports. 2024;44(7). doi:10.1042/bsr20240367

BibTeX
@article{Gaballah2024,
  author = {Gaballah, Aliaa I and Elsherbiny, Aliaa A and Sharaky, Marwa and Hamed, Najat O and Raslan, Nahed A and Almilaibary, Abdullah and Fayyad, Reda Mohamed Abdrabbou and Ousman, Mona S and Hamdan, Ahmed M E and Fahim, Sally A},
  title = {Dexamethasone–tamoxifen combination exerts synergistic therapeutic effects in tamoxifen-resistance breast cancer cells},
  journal = {Bioscience Reports},
  year = {2024},
  volume = {44},
  number = {7},
  doi = {10.1042/bsr20240367}
}
Kostenlos starten →